CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
26 Apr 2024: Breast cancer drug Enhertu’s breakthrough results unveiled at GBCC 2024
- GBCC symposium reveals Enhertu’s breakthrough in HER2+ breast cancer: data presented highlights significant improvements in PFS and OS as compared to Kadcyla
- Enhertu outperforms Kadcyla, extending PFS over four times (28.8 months vs 6.8 months) with 36% reduced risk of death in Destiny-breast03 study
- Comparable safety profiles between Enhertu and Kadcyla with no grade 4 or 5 drug-related lung complications reported, bolstering Enhertu’s safety profile
- Enhertu is recommended as SOC (category 1, preferred) in second-line treatment for HER2-positive mbc treatment in the NCCN and ESMO guidelines
